Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | LY3300054 |
Trade Name | |
Synonyms | Lodapolimab |
Drug Descriptions |
LY3300054 (lodapolimab), is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29712568). |
DrugClasses | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 |
CAS Registry Number | 2118349-31-6 |
NCIT ID | C128138 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
LY3200882 + LY3300054 | LY3200882 LY3300054 | 0 | 0 |
LY3300054 | LY3300054 | 0 | 1 |
LY3300054 + LY3321367 | LY3300054 LY3321367 | 0 | 1 |
LY3300054 + LY3381916 | LY3300054 LY3381916 | 0 | 1 |
LY3300054 + Necitumumab | LY3300054 Necitumumab | 0 | 1 |
LY3300054 + Prexasertib | LY3300054 Prexasertib | 0 | 1 |
LY3300054 + Ramucirumab | LY3300054 Ramucirumab | 0 | 1 |